All News

Fonseca Talks Future Research Comparing First- Vs Second-Line Daratumumab for Transplant-Ineligible Myeloma
January 26, 2022

CancerNetwork® spoke with Rafael Fonseca, MD, about future efforts to compare use of daratumumab-containing regimens as either frontline or second-line therapy in patients with multiple myeloma that are transplant ineligible.

End-of-Year Wrap Up: Unpacking Updates in Women’s Cancer from 2021
January 26, 2022

In an interview with CancerNetwork, Don Dizon, MD, FACP, FASCO, discusses key updates that read out in both the gynecologic oncology and breast cancer fields over the course of 2021.

FDA Accepts Review of Supplemental Biologics License Application for First-Line Cemiplimab/Chemo in Advanced NSCLC
January 26, 2022

The supplemental biologics license application for cemiplimab plus chemotherapy for patients with advanced non–small cell lung cancer was based on findings from the phase 3 EMPOWER-Lung 3 study and was accepted for review by the FDA.

FDA Approves Tebentafusp for Patients With Metastatic Uveal Melanoma and HLA-A*02:01
January 26, 2022

Tebentafusp has been approved by the FDA based on results of the phase 3 IMCgp100-202 trial for patients harboring HLA-A*02:01 with metastatic uveal melanoma.

Matthew S. Davids, MD, MMSc, Discusses Extended Use of Venetoclax in CLL
January 26, 2022

Matthew S. Davids, MD, MMSc, spoke about the benefit of venetoclax combinations in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Hong Kong Department of Health Approves Pemigatinib for Adults With FGFR2+ Locally Advanced/Metastatic Cholangiocarcinoma
January 25, 2022

Pemigatinib is a new treatment option following approval from the Hong Kong Department of Health for patients with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement following progression on at least 1 prior line of therapy.

Ripretinib Does Not Meet Primary End Point vs Sunitinib for Pretreated GIST in Phase 3 INTRIGUE Study
January 25, 2022

Patients with pretreated gastrointestinal stromal tumors who were treated with ripretinib did not reach the primary end point of progression-free survival superiority vs sunitinib in the phase 3 INTRIGUE study.

Melflufen Plus Dexamethasone Improved Survival Over Pomalidomide Combo for Relapsed/Refractory Myeloma
January 25, 2022

Improved progression-free survival was observed when treating patients with relapsed/refractory multiple myeloma with melphalan flufenamide plus dexamethasone compared with pomalidomide plus dexamethasone.

Amitkumar Mehta, MD, Discusses the Role of Parsaclisib in Relapsed/Refractory MCL
January 25, 2022

Amitkumar Mehta, MD, discusses the role of parsaclisib and how it fits into the treatment landscape of relapsed/refractory mantle cell lymphoma.

Sugemalimab/Chemotherapy Combo Yields Statistically Significant Improvement in Overall Survival vs Placebo for NSCLC
January 25, 2022

Patients with stage IV non–small cell lung cancer treated with sugemalimab plus chemotherapy experienced a prolonged overall survival benefit compared with those who received placebo and chemotherapy.